These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 9880128)

  • 1. Proliferation of human peripheral blood mononuclear cells during calcium channel blockade.
    Lijnen P; Fagard R; Petrov V
    Am J Hypertens; 1998 Dec; 11(12):1461-8. PubMed ID: 9880128
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mibefradil-induced inhibition of proliferation of human peripheral blood mononuclear cells.
    Lijnen P; Fagard R; Petrov V
    J Cardiovasc Pharmacol; 1999 Apr; 33(4):595-604. PubMed ID: 10218730
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proliferation of human peripheral blood mononuclear cells during calcium entry blockade. Role of protein kinase C.
    Lijnen P; Petrov V
    Methods Find Exp Clin Pharmacol; 1999 May; 21(4):253-9. PubMed ID: 10399131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of proliferation of human peripheral blood mononuclear cells by calcium antagonists. Role of interleukin-2.
    Petrov V; Lijnen P
    Methods Find Exp Clin Pharmacol; 2000; 22(1):19-23. PubMed ID: 10791290
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytosolic calcium and lymphoproliferative response during calcium antagonism in men.
    Lijnen P; Fagard R; Petrov V
    Eur J Clin Pharmacol; 1999 Feb; 54(12):911-5. PubMed ID: 10192750
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Calcium channel blockers inhibit cellular uptake of thymidine, uridine and leucine: the incorporation of these molecules into DNA, RNA and protein in the presence of calcium channel blockers is not a valid measure of lymphocyte activation.
    Weir MR; Peppler R; Gomolka D; Handwerger BS
    Immunopharmacology; 1993; 25(1):75-82. PubMed ID: 7686541
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mibefradil, A T-type calcium channel antagonist in Y1 cells.
    Esneu M; Gallo-Payet N; Payet MD
    Endocr Res; 1998; 24(3-4):449-54. PubMed ID: 9888524
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potent vasodilatory with minor cardiodepressant actions of mibefradil in human cardiac tissue.
    Brixius K; Mohr V; Müller-Ehmsen J; Hoischen S; Münch G; Schwinger RH
    Br J Pharmacol; 1998 Sep; 125(1):41-8. PubMed ID: 9776342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Voltage-dependent blockade of diverse types of voltage-gated Ca2+ channels expressed in Xenopus oocytes by the Ca2+ channel antagonist mibefradil (Ro 40-5967).
    Bezprozvanny I; Tsien RW
    Mol Pharmacol; 1995 Sep; 48(3):540-9. PubMed ID: 7565636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Impact of calcium channel antagonists for estrogen action on the endometrial carcinoma HEC-1A cells].
    Bao XX; Wang JL; Wei LH
    Zhonghua Fu Chan Ke Za Zhi; 2012 Mar; 47(3):212-7. PubMed ID: 22781074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of the novel T-type calcium channel antagonist mibefradil on human myocardial contractility in comparison with nifedipine and verapamil.
    Cremers B; Flesch M; Südkamp M; Böhm M
    J Cardiovasc Pharmacol; 1997 May; 29(5):692-6. PubMed ID: 9213214
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mibefradil prevents neointima formation after vascular injury in rats. Possible role of the blockade of the T-type voltage-operated calcium channel.
    Schmitt R; Clozel JP; Iberg N; Bühler FR
    Arterioscler Thromb Vasc Biol; 1995 Aug; 15(8):1161-5. PubMed ID: 7627710
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mibefradil- and omega-conotoxin GVIA-induced inhibition of noradrenaline release from the sympathetic nerves of the human heart.
    Göthert M; Molderings GJ
    Naunyn Schmiedebergs Arch Pharmacol; 1997 Dec; 356(6):860-3. PubMed ID: 9453476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human vascular to cardiac tissue selectivity of L- and T-type calcium channel antagonists.
    Sarsero D; Fujiwara T; Molenaar P; Angus JA
    Br J Pharmacol; 1998 Sep; 125(1):109-19. PubMed ID: 9776350
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of Ca2+ channel blockers on Ca2+ loading induced by metabolic inhibition and hyperkalemia in cardiomyocytes.
    Tang T; Duffield R; Ho AK
    Eur J Pharmacol; 1998 Nov; 360(2-3):205-11. PubMed ID: 9851587
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blockade of receptor-operated calcium channels by mibefradil (Ro 40-5967): effects on intracellular calcium and platelet aggregation.
    Hahn M; Tkachuk VA; Bochkov VN; Cheglakov IB; Clozel JP
    Cardiovasc Drugs Ther; 1995 Dec; 9(6):815-21. PubMed ID: 8850387
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative pharmacological properties among calcium channel blockers: T-channel versus L-channel blockade.
    Noll G; Lüscher TF
    Cardiology; 1998; 89 Suppl 1():10-5. PubMed ID: 9570424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Actions of mibefradil, efonidipine and nifedipine block of recombinant T- and L-type Ca channels with distinct inhibitory mechanisms.
    Lee TS; Kaku T; Takebayashi S; Uchino T; Miyamoto S; Hadama T; Perez-Reyes E; Ono K
    Pharmacology; 2006; 78(1):11-20. PubMed ID: 16899990
    [TBL] [Abstract][Full Text] [Related]  

  • 19. T- and L-type Ca2+-channel antagonists reduce contractility in guinea pig cardiac myocytes.
    Hoischen S; Brixius K; Schwinger RH
    J Cardiovasc Pharmacol; 1998 Aug; 32(2):323-30. PubMed ID: 9700997
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative effects of T-type and L-type Ca(2+)-antagonists against noradrenaline-induced contractions of human vas deferens.
    Amobi N; Guillebaud J; Smith CH
    BJU Int; 2010 Aug; 106(4):578-85. PubMed ID: 20002677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.